Dr. Kapoor on LUGPA's Legislative Advocacy

Deepak A. Kapoor, MD
Published: Friday, Nov 06, 2015



Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association’s (LUGPA’s) chairman of health policy, discusses LUGPA’s legislative advocacy efforts.

This year represents the most successful year of legislative advocacy for LUGPA, Kapoor says. The organization commented on outpatient prospective payment system (OPPS) and influenced changes in reimbursements for GreenLight laser therapy and extracorporeal shock wave lithotripsy (ESWL).

In addition, LUGPA also commented on a proposal by the Centers for Medicare and Medicaid Services (CMS) that would have classified radiation for prostate and breast cancers under a “simple” code, resulting in a 30% payment cut. The proposal, which is part of CMS’s preliminary physician fee schedule, was recently deferred pending further studies.



Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association’s (LUGPA’s) chairman of health policy, discusses LUGPA’s legislative advocacy efforts.

This year represents the most successful year of legislative advocacy for LUGPA, Kapoor says. The organization commented on outpatient prospective payment system (OPPS) and influenced changes in reimbursements for GreenLight laser therapy and extracorporeal shock wave lithotripsy (ESWL).

In addition, LUGPA also commented on a proposal by the Centers for Medicare and Medicaid Services (CMS) that would have classified radiation for prostate and breast cancers under a “simple” code, resulting in a 30% payment cut. The proposal, which is part of CMS’s preliminary physician fee schedule, was recently deferred pending further studies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x